Receptor News and Research

RSS

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that TF12, in combination with radiolabeled peptides, produced specific, fast, high-contrast imaging and pretargeted radioimmunotherapy of epithelial cancers that include cancers of the prostate and the ovary.

14 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the patients for up to five years.

14 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

The College of American Pathologists and the American Society of Clinical Oncology today issued a joint guideline aimed at improving the accuracy of immunohistochemistry testing for the expression status of estrogen and progesterone receptors in breast cancer. The two groups conducted a systematic review of medical research literature in partnership with Cancer Care Ontario to develop the recommendations.

14 Jun 2010

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

A virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins. The dual-receptor observation suggests a way brain and spinal cord nerve damage might be triggered in susceptible young adults afflicted with multiple sclerosis.

11 Jun 2010

Phase II study results of riociguat for CTEPH and PAH published online

Bayer HealthCare Pharmaceuticals, Inc. today announced that the study "Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study" was published online this week by the European Respiratory Journal. Results of this study to assess the safety, tolerability and the feasibility of individual dose titration of riociguat were previously presented at the 2009 International Conference of the American Thoracic Society.

11 Jun 2010

Trevena's scientists present research data on GPCR biased ligands at two scientific conferences

Trevena Inc., a leader in the discovery of G-protein coupled receptor biased ligands, today announced that its scientists are presenting research data at two scientific conferences. These oral presentations highlight Trevena's research demonstrating that ligand bias at the angiotensin II type I receptor translates into differentiable and beneficial cardiovascular pharmacology in vivo.

11 Jun 2010

Study results of genes regulated by ERB published in Journal of Biological Chemistry

Bionovo Inc. today announced the publication of results from a study demonstrating the three distinct classes of genes regulated by estrogen receptor beta. The results are published in the Journal of Biological Chemistry. This is an important discovery for future development of selective drugs regulating this pathway.

11 Jun 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.

11 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

UAB researchers win grant to study metastasis of dead cancer cells

Researchers with the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center and UAB Department of Chemistry have won an $805,000 grant from the U.S. Department of Defense Breast Cancer Research Program to study whether dead cancer cells left over after treatment encourage cancer's spread to other parts of the body.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

Mutations in ion channels cause rare inherited pain disorder: Research

A mutation that enhances the function of a specific ion channel has been identified as the cause of a rare inherited pain disorder. The research, published by Cell Press in the June 10 issue of the journal Neuron, proposes a potential treatment for the disorder and may lead to a better understanding of chronic pain in humans.

10 Jun 2010

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

10 Jun 2010

NICE decides not to recommend lapatinib for women with advanced breast cancer

The National Institute for Health and Clinical Excellence has decided not to recommend the oral drug lapatinib (Tyverb) for women with advanced breast cancer, except for use in clinical trials.

10 Jun 2010

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.

9 Jun 2010

CXCR4 protein restores brain damage in multiple sclerosis patients

A protein that helps build the brain in infants and children may aid efforts to restore damage from multiple sclerosis (MS) and other neurodegenerative diseases, researchers at Washington University School of Medicine in St. Louis have found.

9 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010